Catheter-associated thrombosis: Thromboprophylaxis for cancer patients who carry factor V Leiden? [3]

Annals of Oncology

Volumn 17, Issue 3, 2006, Pages 528-529

  Ferretti, Gia ^a   Bria, E ^a   Felici, A ^a   Carlini, P ^a   Giannarelli, D ^a   Ciccarese, M ^a   Papaldo, P ^a   Fabi, A ^a   Gelibter, A ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; FLUOROURACIL;

BREAST CANCER; CANCER; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; GASTROINTESTINAL CARCINOMA; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INDWELLING CATHETER; LETTER; PHLEBOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; CATHETERIZATION; COHORT STUDIES; FACTOR V; HUMANS; MUTATION; NEOPLASMS; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 33644694607     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj021     Document Type: Letter

References (12)

1. Falanga A, Zacharski L. Deep vein thrombosis in cancer: The scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
2. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351: 268-277.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
4. Otterson GA, Monahan BP, Harold N et al. Clinical significance of the FV: Q506 mutation in unselected oncology patients. Am J Med 1996; 101: 406-412.
5. Pihusch R, Danzl G, Scholz M et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002; 94: 3120-3126.
6. Fratino G, Molinari AC, Parodi S. Central venous catheter-related complications in children with oncological/hematological diseases: An observational study of 418 devices. Ann Oncol 2005; 16: 648-654.
7. Verso M, Agnelli A, Bertoglio S et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23: 4057-4062.
8. Couban S, Goodyear M, Burnell M et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23: 4063-4069.
9. Levine M, Kakkar AK. Catheter-associated thrombosis: Thromboprophylaxis or not? J Clin Oncol 2005; 23: 4006-4008.
10. Van Van Rooden CJ, Rosendaal FR, Meinders AE et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 201-206.
11. Fijnheer R, Paijmans B, Verdonck LF et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118: 267-270.
12. Mandala M, Curigliano G, Bucciarelli P et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004; 15: 590-593.